BC Week In Review | Jan 10, 2011
Clinical News

CVBT-141B: Phase IIb data

In a double-blind Phase IIb trial, diabetic wounds treated with CVBT-141B achieved 100% closure in <=5 months compared with 33% of the placebo group whose wounds remained open. Additionally, 57% of patients in the CVBT-141B...
BC Week In Review | Jan 10, 2011
Clinical News

CVBT-141B: Phase IIa data

In a double-blind Phase IIa trial, CVBT-141B healed diabetic wounds about 4.5 times faster than placebo plus standard of care. No significant drug-related adverse events were observed. CardioVascular plans to apply for Fast Track Designation...
BC Week In Review | Dec 6, 2010
Company News

CardioVascular BioTherapeutics, Merck deal

CardioVascular received an exclusive license to use clinical and scientific data from Merck concerning the therapeutic use of fibroblast growth factor-1 (FGF-1) to treat diabetic wounds. CardioVascular plans to use the data as part of...
BC Week In Review | May 26, 2008
Company News

CardioVascular BioTherapeutics, ProDerm L.P. deal

CardioVascular will receive $1-$10 million from ProDerm to fund future clinical trials of CVBT-141B to treat diabetic foot ulcers and venous stasis leg wounds. In return, ProDerm is eligible for 10% royalties on resulting revenues...
BC Week In Review | Oct 8, 2007
Clinical News

CVBT-141B: Phase I data

In a Phase I trial in 8 patients with either diabetic or venous stasis ulcers, topical CVBT-141B was well tolerated. CardioVascular BioTherapeutics Inc. (CVBT), Las Vegas, Nev.   Product: CVBT-141B   Business: Dermatology   Molecular...
BioCentury | Jul 16, 2007
Product Development

New agents in the pipeline

New agents in the pipeline Company Product Target Indication Status J&J Regranex becaplermin Platelet derived growth factor (PDGF) receptor Diabetic foot ulcers Mkt Actelion Tracleer bosentan (A) Endothelin A and B receptors Digital ulcers Approved...
Items per page:
1 - 6 of 6